LU71739A1 - - Google Patents

Info

Publication number
LU71739A1
LU71739A1 LU71739A LU71739A LU71739A1 LU 71739 A1 LU71739 A1 LU 71739A1 LU 71739 A LU71739 A LU 71739A LU 71739 A LU71739 A LU 71739A LU 71739 A1 LU71739 A1 LU 71739A1
Authority
LU
Luxembourg
Application number
LU71739A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of LU71739A1 publication Critical patent/LU71739A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56One oxygen atom and one sulfur atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60Three or more oxygen or sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LU71739A 1974-01-29 1975-01-28 LU71739A1 (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7402810A FR2258841B1 (enExample) 1974-01-29 1974-01-29

Publications (1)

Publication Number Publication Date
LU71739A1 true LU71739A1 (enExample) 1975-06-24

Family

ID=9134107

Family Applications (1)

Application Number Title Priority Date Filing Date
LU71739A LU71739A1 (enExample) 1974-01-29 1975-01-28

Country Status (6)

Country Link
BE (1) BE824885A (enExample)
DE (1) DE2503136A1 (enExample)
FR (1) FR2258841B1 (enExample)
GB (1) GB1495665A (enExample)
LU (1) LU71739A1 (enExample)
NL (1) NL7500613A (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632823B1 (en) * 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
CN102558155A (zh) 2003-01-14 2012-07-11 阿伦纳药品公司 作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
DOP2006000010A (es) 2005-01-10 2006-07-31 Arena Pharm Inc Procedimiento para preparar eteres aromáticos
MX2013003184A (es) 2010-09-22 2013-06-07 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de transtornos relacionados con el mismo.
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
PL3310760T3 (pl) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
KR20190116416A (ko) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
AU2019280822A1 (en) 2018-06-06 2021-01-07 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor

Also Published As

Publication number Publication date
FR2258841B1 (enExample) 1977-11-04
FR2258841A1 (enExample) 1975-08-22
GB1495665A (en) 1977-12-21
BE824885A (fr) 1975-07-28
NL7500613A (nl) 1975-07-31
DE2503136A1 (de) 1975-07-31

Similar Documents

Publication Publication Date Title
FR2258841A1 (enExample)
FI144474A7 (enExample)
AU7253374A (enExample)
CS174562B1 (enExample)
CS176516B1 (enExample)
CS175784B1 (enExample)
CS169394B1 (enExample)
DD115829A1 (enExample)
DD110116A1 (enExample)
CH583190A5 (enExample)
DD117600A1 (enExample)
CH591755A5 (enExample)
CH581359A5 (enExample)
CH566896A5 (enExample)
DD118889A5 (enExample)
DD112978A1 (enExample)
DD114256A1 (enExample)
CH605573A5 (enExample)
DD110415A2 (enExample)
DD112657A1 (enExample)
BG19995A1 (enExample)
CH570131A5 (enExample)
CH566505A5 (enExample)
CH592523A5 (enExample)
DD110935A1 (enExample)